{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,10]],"date-time":"2026-11-10T17:57:15Z","timestamp":1794333435292,"version":"4.9.0"},"reference-count":52,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T00:00:00Z","timestamp":1755216000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Capital Clinical Diagnostic and Therapeutic Technology Research and Demonstration Application of China","award":["Z191100006619026"],"award-info":[{"award-number":["Z191100006619026"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Cancer"],"DOI":"10.1186\/s12885-025-14723-7","type":"journal-article","created":{"date-parts":[[2025,8,15]],"date-time":"2025-08-15T03:51:23Z","timestamp":1755229883000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Peripheral EBV antigen-specific T cell is dysfunctional in Epstein\u2013Barr virus positive diffuse large B-cell lymphoma"],"prefix":"10.1186","volume":"25","author":[{"given":"Liang","family":"Gao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lihong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chao","family":"Xue","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinan","family":"Cen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,8,15]]},"reference":[{"issue":"1","key":"14723_CR1","doi-asserted-by":"publisher","first-page":"140","DOI":"10.1093\/annonc\/mdp505","volume":"21","author":"MK Song","year":"2010","unstructured":"Song MK, Chung JS, Seol YM, Kim SG, Shin HJ, Choi YJ, et al. Influence of low absolute lymphocyte count of patients with nongerminal center type diffuse large B-cell lymphoma with R-CHOP therapy. Ann Oncol. 2010;21(1):140\u20134.","journal-title":"Ann Oncol"},{"issue":"9","key":"14723_CR2","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.1038\/leu.2011.112","volume":"25","author":"RA Wilcox","year":"2011","unstructured":"Wilcox RA, Ristow K, Habermann TM, Inwards DJ, Micallef INM, Johnston PB, et al. The absolute monocyte and lymphocyte prognostic score predicts survival and identifies high-risk patients in diffuse large-B-cell lymphoma. Leukemia. 2011;25(9):1502\u20139.","journal-title":"Leukemia"},{"issue":"9","key":"14723_CR3","doi-asserted-by":"publisher","first-page":"2471","DOI":"10.1007\/s00277-023-05260-z","volume":"102","author":"T-Y Xing","year":"2023","unstructured":"Xing T-Y, Duan Z-W, Wang W-T, Du K-X, Shen H-R, Yin H, et al. Dynamic changes in Circulating EBV-DNA load during treatment have prognostic values in EBV\u2009+\u2009DLBCL-NOS: a Chinese cohort study. Ann Hematol. 2023;102(9):2471\u201381.","journal-title":"Ann Hematol"},{"issue":"2","key":"14723_CR4","doi-asserted-by":"publisher","first-page":"173","DOI":"10.1111\/cei.12682","volume":"182","author":"D C\u00e1rdenas","year":"2015","unstructured":"C\u00e1rdenas D, V\u00e9lez G, Orfao A, Herrera MV, Solano J, Olaya M, et al. Epstein\u2013Barr virus-specific CD8\u2009+\u2009T lymphocytes from diffuse large B cell lymphoma patients are functionally impaired. Clin Exp Immunol. 2015;182(2):173\u201383.","journal-title":"Clin Exp Immunol"},{"issue":"10","key":"14723_CR5","doi-asserted-by":"publisher","first-page":"5854","DOI":"10.4049\/jimmunol.1001024","volume":"186","author":"C Macedo","year":"2011","unstructured":"Macedo C, Webber SA, Donnenberg AD, Popescu I, Hua Y, Green M, et al. EBV-Specific CD8\u2009+\u2009T cells from asymptomatic pediatric thoracic transplant patients carrying chronic high EBV loads display contrasting features: activated phenotype and exhausted function. J Immunol. 2011;186(10):5854\u201362.","journal-title":"J Immunol"},{"issue":"4","key":"14723_CR6","doi-asserted-by":"publisher","first-page":"477","DOI":"10.1016\/S0047-6374(03)00026-5","volume":"124","author":"Q Ouyang","year":"2003","unstructured":"Ouyang Q, Wagner WM, Walter S, Muller CA, Wikby A, Aubert G, et al. An age-related increase in the number of CD8\u2009+\u2009T cells carrying receptors for an immunodominant Epstein\u2013Barr virus (EBV) epitope is counteracted by a decreased frequency of their antigen-specific responsiveness. Mech Ageing Dev. 2003;124(4):477\u201385.","journal-title":"Mech Ageing Dev"},{"issue":"12","key":"14723_CR7","doi-asserted-by":"publisher","first-page":"6183","DOI":"10.4049\/jimmunol.170.12.6183","volume":"170","author":"NA Marshall","year":"2003","unstructured":"Marshall NA, Vickers MA, Barker RN. Regulatory T cells secreting IL-10 dominate the immune response to EBV latent membrane protein 1. J Immunol. 2003;170(12):6183\u20139.","journal-title":"J Immunol"},{"key":"14723_CR8","doi-asserted-by":"publisher","first-page":"58","DOI":"10.1016\/j.semcancer.2015.04.006","volume":"34","author":"R Dolcetti","year":"2015","unstructured":"Dolcetti R. Cross-talk between Epstein\u2013Barr virus and microenvironment in the pathogenesis of lymphomas. Sem Cancer Biol. 2015;34:58\u201369.","journal-title":"Sem Cancer Biol"},{"issue":"1","key":"14723_CR9","doi-asserted-by":"publisher","first-page":"587","DOI":"10.1146\/annurev.immunol.25.022106.141553","volume":"25","author":"AD Hislop","year":"2007","unstructured":"Hislop AD, Taylor GS, Sauce D, Rickinson AB. Cellular responses to viral infection in humans: lessons from Epstein\u2013Barr virus. Annu Rev Immunol. 2007;25(1):587\u2013617.","journal-title":"Annu Rev Immunol"},{"issue":"6","key":"14723_CR10","doi-asserted-by":"publisher","first-page":"574","DOI":"10.1159\/000479749","volume":"9","author":"Y Lu","year":"2017","unstructured":"Lu Y, Qin Z, Wang J, Zheng X, Lu J, Zhang X, et al. Epstein\u2013Barr virus miR-BART6-3p inhibits the RIG-I pathway. J Innate Immun. 2017;9(6):574\u201386.","journal-title":"J Innate Immun"},{"issue":"10","key":"14723_CR11","doi-asserted-by":"publisher","first-page":"4062","DOI":"10.4049\/jimmunol.1501605","volume":"198","author":"MJG Hooykaas","year":"2017","unstructured":"Hooykaas MJG, van Gent M, Soppe JA, Kruse E, Boer IGJ, van Leenen D, et al. EBV MicroRNA BART16 suppresses type I IFN signaling. J Immunol. 2017;198(10):4062\u201373.","journal-title":"J Immunol"},{"issue":"10","key":"14723_CR12","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1084\/jem.20160248","volume":"213","author":"T Tagawa","year":"2016","unstructured":"Tagawa T, Albanese M, Bouvet M, Moosmann A, Mautner J, Heissmeyer V, et al. Epstein\u2013Barr viral MiRNAs inhibit antiviral CD4\u2009+\u2009T cell responses targeting IL-12 and peptide processing. J Exp Med. 2016;213(10):2065\u201380.","journal-title":"J Exp Med"},{"key":"14723_CR13","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1016\/S1074-7613(95)80040-9","volume":"2","author":"CL Miller","year":"1995","unstructured":"Miller CL, Burkhard AL, Lee JH, Becky Stealey R, Longnecker JB, Bolen, et al. Integral membrane protein 2 of Epstein\u2013barr virus regulates reactivation from latency through dominant negative effects on protein-tyrosine kinases. Immunity. 1995;2:155\u201366.","journal-title":"Immunity"},{"issue":"1","key":"14723_CR14","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1038\/35095584","volume":"1","author":"DA Thorley Lawson","year":"2001","unstructured":"Thorley Lawson DA. Epstein\u2013Barr virus: exploiting the immune system. Nat Rev Immunol. 2001;1(1):75\u201382.","journal-title":"Nat Rev Immunol"},{"issue":"11","key":"14723_CR15","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.3390\/cancers13112717","volume":"13","author":"P Chabay","year":"2021","unstructured":"Chabay P. Advances in the pathogenesis of EBV-associated diffuse large B cell lymphoma. Cancers (Basel). 2021;13(11):2717.","journal-title":"Cancers (Basel)"},{"issue":"3","key":"14723_CR16","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1182\/blood-2013-03-489708","volume":"122","author":"CY Ok","year":"2013","unstructured":"Ok CY, Papathomas TG, Medeiros LJ, Young KH. EBV-positive diffuse large B-cell lymphoma of the elderly. Blood. 2013;122(3):328\u201340.","journal-title":"Blood"},{"issue":"20","key":"14723_CR17","doi-asserted-by":"publisher","first-page":"1413","DOI":"10.1056\/NEJM199805143382003","volume":"338","author":"D Liebowitz","year":"1998","unstructured":"Liebowitz D. Epstein\u2013Barr virus and a cellular signaling pathway in lymphomas from immunosuppressed patients. N Engl J Med. 1998;338(20):1413\u201321.","journal-title":"N Engl J Med"},{"issue":"14","key":"14723_CR18","doi-asserted-by":"publisher","first-page":"3321","DOI":"10.1002\/j.1460-2075.1994.tb06634.x","volume":"13","author":"AJ Sinclair","year":"1994","unstructured":"Sinclair AJ, Palmero L, Peters G, FarrelI PJ. EBNA-2 and EBNA-LP cooperate to cause go to G1 transition during immortalization of resting human B lymphocytes by Epstein\u2013Barr virus. EMBO J. 1994;13(14):3321\u20138.","journal-title":"EMBO J"},{"issue":"20","key":"14723_CR19","doi-asserted-by":"publisher","first-page":"11538","DOI":"10.1128\/JVI.00581-07","volume":"81","author":"T Crough","year":"2007","unstructured":"Crough T, Fazou C, Weiss J, Campbell S, Davenport MP, Bell SC, et al. Symptomatic and asymptomatic viral recrudescence in solid-organ transplant recipients and its relationship with the Antigen-Specific CD8\u2009+\u2009T-Cell response. J Virol. 2007;81(20):11538\u201342.","journal-title":"J Virol"},{"issue":"1","key":"14723_CR20","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1086\/523652","volume":"197","author":"C La Rosa","year":"2008","unstructured":"La Rosa C, Krishnan A, Longmate J, Martinez J, Manchanda P, Lacey Simon F, et al. Programmed Death\u20131 expression in liver transplant recipients as a prognostic indicator of cytomegalovirus disease. J Infect Dis. 2008;197(1):25\u201333.","journal-title":"J Infect Dis"},{"issue":"9","key":"14723_CR21","doi-asserted-by":"publisher","first-page":"3166","DOI":"10.1182\/blood-2005-01-0432","volume":"106","author":"E Piriou","year":"2005","unstructured":"Piriou E, van Dort K, Nanlohy NM, van Oers MHJ, Miedema F, van Baarle D. Loss of EBNA1-specific memory CD4\u2009+\u2009and CD8\u2009+\u2009T cells in HIV-infected patients progressing to AIDS-related non-Hodgkin lymphoma. Blood. 2005;106(9):3166\u201374.","journal-title":"Blood"},{"issue":"1","key":"14723_CR22","doi-asserted-by":"publisher","first-page":"319","DOI":"10.4049\/jimmunol.0803647","volume":"183","author":"EM Iancu","year":"2009","unstructured":"Iancu EM, Corthesy P, Baumgaertner P, Devevre E, Voelter V, Romero P, et al. Clonotype selection and composition of human CD8 T cells specific for persistent herpes viruses varies with differentiation but is stable over time. J Immunol. 2009;183(1):319\u201331.","journal-title":"J Immunol"},{"issue":"4","key":"14723_CR23","doi-asserted-by":"publisher","first-page":"577","DOI":"10.1111\/j.1365-2567.2008.03035.x","volume":"127","author":"VJ Vanhoutte","year":"2009","unstructured":"Vanhoutte VJ, McAulay KA, McCarrell E, Turner M, Crawford DH, Haque T. Cytolytic mechanisms and T-cell receptor V\u03b2 usage by ex vivo generated Epstein\u2013Barr virus-specific cytotoxic T lymphocytes. Immunology. 2009;127(4):577\u201386.","journal-title":"Immunology"},{"issue":"1","key":"14723_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3390\/pathogens7010028","volume":"7","author":"S Dojcinov","year":"2018","unstructured":"Dojcinov S, Fend F, Quintanilla Martinez L. EBV-Positive lymphoproliferations of B- T- and NK-Cell derivation in Non-Immunocompromised hosts. Pathogens. 2018;7(1):28.","journal-title":"Pathogens"},{"issue":"6","key":"14723_CR25","doi-asserted-by":"publisher","first-page":"1566","DOI":"10.1002\/eji.200940000","volume":"40","author":"M Guerreiro","year":"2010","unstructured":"Guerreiro M, Na IK, Letsch A, Haase D, Bauer S, Meisel C, et al. Human peripheral blood and bone marrow Epstein\u2013Barr virus-specific T-cell repertoire in latent infection reveals distinct memory T-cell subsets. Eur J Immunol. 2010;40(6):1566\u201376.","journal-title":"Eur J Immunol"},{"issue":"11","key":"14723_CR26","doi-asserted-by":"publisher","first-page":"5356","DOI":"10.4049\/jimmunol.1201867","volume":"189","author":"MJ Smithey","year":"2012","unstructured":"Smithey MJ, Li G, Venturi V, Davenport MP, Nikolich-\u017dugich J. Lifelong persistent viral infection alters the naive T cell pool, impairing CD8 T cell immunity in late life. J Immunol. 2012;189(11):5356\u201366.","journal-title":"J Immunol"},{"issue":"2","key":"14723_CR27","doi-asserted-by":"publisher","first-page":"1037","DOI":"10.4049\/jimmunol.174.2.1037","volume":"174","author":"A Harari","year":"2005","unstructured":"Harari A, Vallelian F, Meylan PR, Pantaleo G. Functional heterogeneity of memory CD4 T cell responses in different conditions of antigen exposure and persistence. J Immunol. 2005;174(2):1037\u201345.","journal-title":"J Immunol"},{"issue":"1","key":"14723_CR28","doi-asserted-by":"publisher","first-page":"10","DOI":"10.1038\/s41590-017-0006-x","volume":"19","author":"J Nikolich-\u017dugich","year":"2017","unstructured":"Nikolich-\u017dugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2017;19(1):10\u20139.","journal-title":"Nat Immunol"},{"issue":"12","key":"14723_CR29","doi-asserted-by":"publisher","first-page":"3525","DOI":"10.1002\/eji.200425324","volume":"34","author":"A Harari","year":"2004","unstructured":"Harari A, Vallelian F, Pantaleo G. Phenotypic heterogeneity of antigen-specific CD4 T cells under different conditions of antigen persistence and antigen load. Eur J Immunol. 2004;34(12):3525\u201333.","journal-title":"Eur J Immunol"},{"issue":"12","key":"14723_CR30","doi-asserted-by":"publisher","first-page":"2367","DOI":"10.1038\/leu.2014.137","volume":"28","author":"D Rossille","year":"2014","unstructured":"Rossille D, Gressier M, Damotte D, Maucort-Boulch D, Pangault C, Semana G, et al. High level of soluble programmed cell death ligand 1 in blood impacts overall survival in aggressive diffuse large B-cell lymphoma: results from a French multicenter clinical trial. Leukemia. 2014;28(12):2367\u201375.","journal-title":"Leukemia"},{"issue":"3","key":"14723_CR31","doi-asserted-by":"publisher","first-page":"718","DOI":"10.3324\/haematol.2019.243626","volume":"106","author":"A Matias","year":"2020","unstructured":"Matias A, Suvi-Katri L, Oscar B, Satu M, Judit M\u00e9sz\u00e1ros J, Marja-Liisa K-L, et al. Immune cell constitution in the tumor microenvironment predicts the outcome in diffuse large B-cell lymphoma. Haematologica. 2020;106(3):718\u201329.","journal-title":"Haematologica"},{"issue":"7","key":"14723_CR32","doi-asserted-by":"publisher","first-page":"1816","DOI":"10.1182\/bloodadvances.2020003080","volume":"5","author":"M Roussel","year":"2021","unstructured":"Roussel M, Le KS, Granier C, Llamas Gutierrez F, Foucher E, Le Gallou S, et al. Functional characterization of PD1\u2009+\u2009TIM3\u2009+\u2009tumor-infiltrating T cells in DLBCL and effects of PD1 or TIM3 Blockade. Blood Adv. 2021;5(7):1816\u201329.","journal-title":"Blood Adv"},{"issue":"3","key":"14723_CR33","doi-asserted-by":"publisher","first-page":"835","DOI":"10.3390\/cancers15030835","volume":"15","author":"T Takahara","year":"2023","unstructured":"Takahara T, Nakamura S, Tsuzuki T, Satou A. The immunology of DLBCL. Cancers (Basel). 2023;15(3):835.","journal-title":"Cancers (Basel)"},{"issue":"4","key":"14723_CR34","doi-asserted-by":"publisher","first-page":"670","DOI":"10.1016\/j.immuni.2007.09.006","volume":"27","author":"EJ Wherry","year":"2007","unstructured":"Wherry EJ, Ha SJ, Kaech SM, Haining WN, Sarkar S, Kalia V, et al. Molecular signature of CD8\u2009+\u2009T cell exhaustion during chronic viral infection. Immunity. 2007;27(4):670\u201384.","journal-title":"Immunity"},{"issue":"12","key":"14723_CR35","doi-asserted-by":"publisher","first-page":"1344","DOI":"10.1158\/2326-6066.CIR-15-0097","volume":"3","author":"DS Thommen","year":"2015","unstructured":"Thommen DS, Schreiner J, M\u00fcller P, Herzig P, Roller A, Belousov A, et al. Progression of lung cancer is associated with increased dysfunction of T cells defined by coexpression of multiple inhibitory receptors. Cancer Immunol Res. 2015;3(12):1344\u201355.","journal-title":"Cancer Immunol Res"},{"key":"14723_CR36","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1146\/annurev.immunol.26.021607.090331","volume":"26","author":"ME Keir","year":"2008","unstructured":"Keir ME, Butte MJ, Freeman GJ, Sharpe AH. PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol. 2008;26:677\u2013704.","journal-title":"Annu Rev Immunol"},{"issue":"3","key":"14723_CR37","doi-asserted-by":"publisher","first-page":"634","DOI":"10.1002\/1521-4141(200203)32:3<634::AID-IMMU634>3.0.CO;2-9","volume":"32","author":"L Carter","year":"2002","unstructured":"Carter L, Fouser LA, Jussif J, Fitz L, Deng B, Wood CR, et al. PD-1:PD-L inhibitory pathway affects both CD4(+) and CD8(+) T cells and is overcome by IL-2. Eur J Immunol. 2002;32(3):634\u201343.","journal-title":"Eur J Immunol"},{"key":"14723_CR38","doi-asserted-by":"crossref","unstructured":"Hussein Akil HB, Aitamer M, Vignoles C, Abraham J, Gachard N, Olivrie Agn\u00e8s, Guyot A, Gobbo J, Feuillard J. Hamasseh Shirvani & Danielle troutaud. Analysis of CD20 and PD-L1 levels on small extracellular vesicles (sEV) produced by DLBCL cells and EBV-transformed B cells, and potential role in T cell Inhibition. Exp Hematol Oncol. 2024(13):53.","DOI":"10.1186\/s40164-024-00518-2"},{"key":"14723_CR39","doi-asserted-by":"publisher","first-page":"105999","DOI":"10.1016\/j.intimp.2019.105999","volume":"77","author":"M Xie","year":"2019","unstructured":"Xie M, Huang X, Ye X, Qian W. Prognostic and clinicopathological significance of PD-1\/PD-L1 expression in the tumor microenvironment and neoplastic cells for lymphoma. Int Immunopharmacol. 2019;77:105999.","journal-title":"Int Immunopharmacol"},{"issue":"11","key":"14723_CR40","doi-asserted-by":"publisher","first-page":"3077","DOI":"10.1002\/cam4.874","volume":"5","author":"W Zhang","year":"2016","unstructured":"Zhang W, Bai JF, Zuo MX, Cao XX, Chen M, Zhang Y, et al. PD-1 expression on the surface of peripheral blood CD4(+) T cell and its association with the prognosis of patients with diffuse large B-cell lymphoma. Cancer Med. 2016;5(11):3077\u201384.","journal-title":"Cancer Med"},{"issue":"6","key":"14723_CR41","doi-asserted-by":"publisher","first-page":"e002323","DOI":"10.1136\/jitc-2020-002323","volume":"9","author":"C Jimenez Cortegana","year":"2021","unstructured":"Jimenez Cortegana C, Palazon Carrion N, Martin Garcia Sancho A, Nogales-Fernandez E, Carnicero-Gonzalez F, Rios-Herranz E, et al. Circulating myeloid-derived suppressor cells and regulatory T cells as immunological biomarkers in refractory\/relapsed diffuse large B-cell lymphoma: translational results from the R2-GDP-GOTEL trial. J Immunother Cancer. 2021;9(6):e002323.","journal-title":"J Immunother Cancer"},{"issue":"Supplement 1","key":"14723_CR42","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1182\/blood-2021-151824","volume":"138","author":"E Yilmaz","year":"2021","unstructured":"Yilmaz E, Lakhotia R, Pittaluga S. Phase 2 study of nivolumab in Epstein\u2013Barr virus (EBV)-positive lymphoproliferative disorders and EBV-positive non-Hodgkin lymphomas. Blood. 2021;138(Supplement 1):4504.","journal-title":"Blood"},{"issue":"9","key":"14723_CR43","first-page":"1680","volume":"19","author":"JP Chou","year":"2013","unstructured":"Chou JP, Effros RB. T cell replicative senescence in human aging. Curr Pharm Design. 2013;19(9):1680\u201398.","journal-title":"Curr Pharm Design"},{"issue":"1","key":"14723_CR44","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1002\/cyto.a.22351","volume":"85","author":"A Larbi","year":"2014","unstructured":"Larbi A, Fulop T. From truly Na\u00efve to exhausted senescent T cells: when markers predict functionality. Cytometry Part A. 2014;85(1):25\u201335.","journal-title":"Cytometry Part A"},{"issue":"4","key":"14723_CR45","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1007\/s00262-016-1803-z","volume":"65","author":"H Kared","year":"2016","unstructured":"Kared H, Martelli S, Ng TP, Pender SLF, Larbi A. CD57 in human natural killer cells and T-lymphocytes. Cancer Immunol Immunother. 2016;65(4):441\u201352.","journal-title":"Cancer Immunol Immunother"},{"issue":"8","key":"14723_CR46","doi-asserted-by":"publisher","first-page":"3883","DOI":"10.4049\/jimmunol.1402202","volume":"194","author":"MC Albareda","year":"2015","unstructured":"Albareda MC, Perez-Mazliah D, Natale MA, Castro-Eiro M, Alvarez MG, Viotti R, et al. Perturbed T cell IL-7 receptor signaling in chronic Chagas disease. J Immunol. 2015;194(8):3883\u20139.","journal-title":"J Immunol"},{"issue":"2","key":"14723_CR47","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1016\/j.coi.2012.12.003","volume":"25","author":"J Crespo","year":"2013","unstructured":"Crespo J, Sun H, Welling TH, Tian Z, Zou W. T cell anergy, exhaustion, senescence, and stemness in the tumor microenvironment. Curr Opin Immunol. 2013;25(2):214\u201321.","journal-title":"Curr Opin Immunol"},{"issue":"9","key":"14723_CR48","doi-asserted-by":"publisher","first-page":"1449","DOI":"10.1038\/s41591-018-0101-z","volume":"24","author":"ST Kim","year":"2018","unstructured":"Kim ST, Cristescu R, Bass AJ, Kim K-M, Odegaard JI, Kim K, et al. Comprehensive molecular characterization of clinical responses to PD-1 inhibition in metastatic gastric cancer. Nat Med. 2018;24(9):1449\u201358.","journal-title":"Nat Med"},{"issue":"2","key":"14723_CR49","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-003527","volume":"10","author":"KM Mahoney","year":"2022","unstructured":"Mahoney KM, Ross-Macdonald P, Yuan L, Song L, Veras E, Wind-Rotolo M, et al. Soluble PD-L1 as an early marker of progressive disease on nivolumab. J Immunother Cancer. 2022;10(2): e003527.","journal-title":"J Immunother Cancer"},{"issue":"19","key":"14723_CR50","first-page":"2125","volume":"36","author":"C Robert","year":"2017","unstructured":"Robert C, Pier LZ, Michelle AF, Philippe A, Nathalie AJ, Pauline B, et al. Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic hodgkin lymphoma. J Clin Oncol. 2017;36(19):2125\u201332.","journal-title":"J Clin Oncol"},{"key":"14723_CR51","doi-asserted-by":"publisher","first-page":"104420","DOI":"10.1016\/j.ebiom.2022.104420","volume":"87","author":"T Wen","year":"2023","unstructured":"Wen T, Sun G, Jiang W, He X, Shi Y, Ma F, et al. Histone deacetylases inhibitor chidamide synergizes with humanized PD1 antibody to enhance T-cell chemokine expression and augment Ifn-\u03b3 response in NK-T cell lymphoma. eBioMedicine. 2023;87:104420.","journal-title":"eBioMedicine"},{"issue":"2","key":"14723_CR52","doi-asserted-by":"publisher","first-page":"e006007","DOI":"10.1136\/jitc-2022-006007","volume":"11","author":"RC Augustin","year":"2023","unstructured":"Augustin RC, Bao R, Luke JJ. Targeting Cbl-b in cancer immunotherapy. J Immunother Cancer. 2023;11(2):e006007.","journal-title":"J Immunother Cancer"}],"container-title":["BMC Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12885-025-14723-7\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12885-025-14723-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,9]],"date-time":"2025-09-09T04:43:56Z","timestamp":1757393036000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmccancer.biomedcentral.com\/articles\/10.1186\/s12885-025-14723-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,15]]},"references-count":52,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["14723"],"URL":"https:\/\/doi.org\/10.1186\/s12885-025-14723-7","relation":{},"ISSN":["1471-2407"],"issn-type":[{"value":"1471-2407","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,15]]},"assertion":[{"value":"23 June 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The Ethics Committee of Peking University First Hospital provided ethical approval (approval NO.2022 244-003) on 22 September 2022. All procedures performed in this study was conducted in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1318"}}